Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Neurocrine Biosciences Inc (NBIX)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Neurocrine Biosciences Inc.
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 914475.
Total stock buying since 2015: $0.
Total stock sales since 2015: $553,389,273.
Total stock option exercises since 2015: $112,361,564.
Table 3. Detailed insider trading at Neurocrine Biosciences Inc (NBIX) , Part 3
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2022-11-08 | Lippoldt Darin (Chief Legal Officer) | Sale | 5,082 | 125.04 | 635,443 |
| 2022-11-08 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 5,082 | 43.24 | 219,745 |
| 2022-11-03 | Cooke Julie (Chief Human Resources Officer) | Sale | 7,264 | 125.00 | 908,036 |
| 2022-11-03 | Cooke Julie (Chief Human Resources Officer) | Option Ex | 7,264 | 81.05 | 588,747 |
| 2022-11-03 | Benevich Eric (Chief Commercial Officer) | Sale | 8,968 | 125.02 | 1,121,179 |
| 2022-11-03 | Benevich Eric (Chief Commercial Officer) | Option Ex | 8,968 | 41.78 | 374,683 |
| 2022-11-03 | Lippoldt Darin (Chief Legal Officer) | Sale | 4,518 | 125.02 | 564,849 |
| 2022-11-03 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 4,518 | 43.24 | 195,358 |
| 2022-11-02 | Cooke Julie (Chief Human Resources Officer) | Sale | 1,144 | 124.97 | 142,963 |
| 2022-11-02 | Cooke Julie (Chief Human Resources Officer) | Option Ex | 1,144 | 81.05 | 92,721 |
| 2022-11-02 | Benevich Eric (Chief Commercial Officer) | Sale | 400 | 125.00 | 50,000 |
| 2022-11-02 | Benevich Eric (Chief Commercial Officer) | Option Ex | 400 | 41.78 | 16,712 |
| 2022-11-02 | Lippoldt Darin (Chief Legal Officer) | Sale | 400 | 125.00 | 50,000 |
| 2022-11-02 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 400 | 43.24 | 17,296 |
| 2022-11-01 | Lippoldt Darin (Chief Legal Officer) | Sale | 10,000 | 120.09 | 1,200,900 |
| 2022-11-01 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 10,000 | 43.24 | 432,400 |
| 2022-10-31 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 1,295 | 114.12 | 147,785 |
| 2022-10-31 | Lyons Gary A (Director) | Sale | 15,000 | 114.76 | 1,721,400 |
| 2022-10-31 | Lyons Gary A (Director) | Option Ex | 15,000 | 12.71 | 190,650 |
| 2022-10-27 | Lippoldt Darin (Chief Legal Officer) | Sale | 4,923 | 115.04 | 566,332 |
| 2022-10-27 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 4,923 | 43.24 | 212,870 |
| 2022-10-26 | Lippoldt Darin (Chief Legal Officer) | Sale | 5,077 | 115.02 | 583,966 |
| 2022-10-26 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 5,077 | 43.24 | 219,529 |
| 2022-10-17 | Benevich Eric (Chief Commercial Officer) | Sale | 9,920 | 110.82 | 1,099,364 |
| 2022-10-04 | Lippoldt Darin (Chief Legal Officer) | Sale | 10,000 | 111.05 | 1,110,450 |
| 2022-10-04 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 10,000 | 43.24 | 432,400 |
| 2022-10-04 | Lyons Gary A (Director) | Sale | 5,000 | 110.54 | 552,710 |
| 2022-10-03 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 1,437 | 106.59 | 153,169 |
| 2022-08-15 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Option Ex | 8,043 | 53.57 | 430,887 |
| 2022-08-12 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 21,533 | 105.95 | 2,281,335 |
| 2022-08-12 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Option Ex | 21,533 | 35.99 | 774,972 |
| 2022-08-05 | Cooke Julie (Chief Human Resources Officer) | Sale | 1,816 | 100.00 | 181,600 |
| 2022-06-27 | Cooke Julie (Chief Human Resources Officer) | Sale | 754 | 100.00 | 75,400 |
| 2022-05-09 | Pops Richard F (Director) | Sale | 15,000 | 76.30 | 1,144,470 |
| 2022-05-09 | Pops Richard F (Director) | Option Ex | 15,000 | 6.66 | 99,900 |
| 2022-04-25 | Lyons Gary A (Director) | Sale | 15,000 | 92.76 | 1,391,400 |
| 2022-04-25 | Lyons Gary A (Director) | Option Ex | 15,000 | 6.66 | 99,900 |
| 2022-04-01 | Rastetter William H (Director) | Sale | 10,728 | 94.93 | 1,018,366 |
| 2022-04-01 | Rastetter William H (Director) | Option Ex | 20,000 | 6.66 | 133,200 |
| 2022-03-22 | Lippoldt Darin (Chief Legal Officer) | Sale | 8,455 | 95.05 | 803,656 |
| 2022-03-18 | Lippoldt Darin (Chief Legal Officer) | Sale | 300 | 95.00 | 28,500 |
| 2022-02-08 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 700 | 79.62 | 55,736 |
| 2022-02-08 | Cooke Julie (Chief Human Resources Officer) | Sale | 700 | 79.56 | 55,689 |
| 2022-02-08 | Roberts Eiry (Chief Medical Officer) | Sale | 980 | 79.52 | 77,930 |
| 2022-02-08 | Abernethy Matt (Chief Financial Officer) | Sale | 980 | 79.65 | 78,057 |
| 2022-02-08 | Benevich Eric (Chief Commercial Officer) | Sale | 980 | 79.67 | 78,072 |
| 2022-02-08 | Gano Kyle (Chief Business Development Officer) | Sale | 980 | 79.67 | 78,078 |
| 2022-02-08 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 701 | 79.53 | 55,750 |
| 2022-02-08 | Lippoldt Darin (Chief Legal Officer) | Sale | 911 | 79.51 | 72,434 |
| 2022-02-08 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 2,274 | 79.49 | 180,767 |
| 2022-02-07 | Boyer David W. (Chief Corp. Affairs Officer) | Sale | 240 | 81.07 | 19,456 |
| 2022-02-07 | Cooke Julie (Chief Human Resources Officer) | Sale | 2,158 | 80.63 | 174,008 |
| 2022-02-07 | Roberts Eiry (Chief Medical Officer) | Sale | 2,744 | 80.78 | 221,668 |
| 2022-02-07 | Abernethy Matt (Chief Financial Officer) | Sale | 3,310 | 80.79 | 267,418 |
| 2022-02-07 | Benevich Eric (Chief Commercial Officer) | Sale | 4,119 | 80.76 | 332,658 |
| 2022-02-07 | Gano Kyle (Chief Business Development Officer) | Sale | 5,900 | 80.76 | 476,466 |
| 2022-02-07 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 2,681 | 80.72 | 216,410 |
| 2022-02-07 | Lippoldt Darin (Chief Legal Officer) | Sale | 3,168 | 80.69 | 255,619 |
| 2022-02-07 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 8,710 | 80.82 | 703,907 |
| 2022-01-24 | Sherwin Stephen A (Director) | Sale | 15,000 | 74.42 | 1,116,375 |
| 2022-01-24 | Sherwin Stephen A (Director) | Option Ex | 15,000 | 6.66 | 99,900 |
| 2022-01-10 | Roberts Eiry (Chief Medical Officer) | Sale | 2,632 | 74.50 | 196,086 |
| 2022-01-05 | Gano Kyle (Chief Business Development Officer) | Sale | 28,266 | 85.50 | 2,416,743 |
| 2022-01-05 | Gano Kyle (Chief Business Development Officer) | Option Ex | 28,266 | 8.66 | 244,783 |
| 2021-12-01 | Abernethy Matt (Chief Financial Officer) | Sale | 1,645 | 82.58 | 135,852 |
| 2021-10-07 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 8,000 | 104.80 | 838,408 |
| 2021-10-07 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 5,000 | 43.24 | 216,200 |
| 2021-10-07 | Lyons Gary A (Director) | Sale | 5,000 | 105.06 | 525,295 |
| 2021-10-04 | Cooke Julie (Chief Human Resources Officer) | Sale | 987 | 101.73 | 100,407 |
| 2021-08-16 | Benevich Eric (Chief Commercial Officer) | Sale | 5,628 | 89.62 | 504,392 |
| 2021-07-27 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 16,709 | 93.80 | 1,567,337 |
| 2021-06-10 | Lyons Gary A (Director) | Sale | 10,000 | 100.27 | 1,002,740 |
| 2021-02-10 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 1,700 | 119.96 | 203,925 |
| 2021-02-10 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Option Ex | 1,700 | 35.99 | 61,183 |
| 2021-02-09 | Lippoldt Darin (Chief Legal Officer) | Sale | 36,194 | 116.64 | 4,221,595 |
| 2021-02-09 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 36,194 | 35.99 | 1,302,622 |
| 2021-02-08 | Cooke Julie (Chief Human Resources Officer) | Sale | 1,338 | 116.74 | 156,199 |
| 2021-02-08 | Roberts Eiry (Chief Medical Officer) | Sale | 2,363 | 116.75 | 275,875 |
| 2021-02-08 | Abernethy Matt (Chief Financial Officer) | Sale | 2,910 | 116.83 | 339,966 |
| 2021-02-08 | Benevich Eric (Chief Commercial Officer) | Sale | 4,270 | 116.83 | 498,868 |
| 2021-02-08 | Gano Kyle (Chief Business Development Officer) | Sale | 3,693 | 116.85 | 431,523 |
| 2021-02-08 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 3,261 | 116.83 | 380,989 |
| 2021-02-08 | Lippoldt Darin (Chief Legal Officer) | Sale | 3,407 | 116.72 | 397,658 |
| 2021-02-08 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 2,708 | 116.69 | 315,991 |
| 2021-02-08 | Bozigian Haig P. (Chief Development Officer) | Sale | 3,842 | 116.81 | 448,776 |
| 2021-02-08 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 10,466 | 116.75 | 1,221,884 |
| 2021-02-05 | Cooke Julie (Chief Human Resources Officer) | Sale | 605 | 113.86 | 68,886 |
| 2021-02-05 | Benevich Eric (Chief Commercial Officer) | Sale | 809 | 114.03 | 92,247 |
| 2021-02-05 | Gano Kyle (Chief Business Development Officer) | Sale | 2,677 | 113.93 | 304,979 |
| 2021-02-05 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 865 | 114.15 | 98,738 |
| 2021-02-05 | Lippoldt Darin (Chief Legal Officer) | Sale | 605 | 114.05 | 69,002 |
| 2021-02-05 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 605 | 113.76 | 68,822 |
| 2021-02-05 | Bozigian Haig P. (Chief Development Officer) | Sale | 704 | 113.79 | 80,108 |
| 2021-02-05 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 2,422 | 114.16 | 276,505 |
| 2021-01-26 | Benevich Eric (Chief Commercial Officer) | Sale | 400 | 120.00 | 48,000 |
| 2021-01-26 | Benevich Eric (Chief Commercial Officer) | Option Ex | 300 | 41.78 | 12,534 |
| 2021-01-26 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 1,100 | 119.97 | 131,964 |
| 2021-01-26 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Option Ex | 1,100 | 35.99 | 39,589 |
| 2021-01-26 | Lyons Gary A (Director) | Sale | 400 | 120.00 | 48,000 |
| 2021-01-25 | Benevich Eric (Chief Commercial Officer) | Sale | 5,077 | 120.03 | 609,372 |
| 2021-01-25 | Benevich Eric (Chief Commercial Officer) | Option Ex | 3,477 | 41.78 | 145,269 |
| 2021-01-25 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 17,570 | 119.97 | 2,107,925 |
| 2021-01-25 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Option Ex | 17,570 | 34.99 | 614,774 |
| 2021-01-25 | Lyons Gary A (Director) | Sale | 1,600 | 120.03 | 192,046 |
| 2021-01-08 | Roberts Eiry (Chief Medical Officer) | Sale | 2,632 | 111.06 | 292,296 |
| 2021-01-08 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 308,250 | 110.22 | 33,973,773 |
| 2021-01-08 | Gorman Kevin Charles (Chief Executive Officer) | Option Ex | 308,250 | 8.65 | 2,667,903 |
| 2020-12-01 | Abernethy Matt (Chief Financial Officer) | Sale | 1,645 | 94.66 | 155,720 |
| 2020-11-12 | Cooke Julie (Chief Human Resources Officer) | Sale | 2,257 | 90.73 | 204,777 |
| 2020-11-12 | Roberts Eiry (Chief Medical Officer) | Sale | 2,257 | 90.74 | 204,809 |
| 2020-11-12 | Abernethy Matt (Chief Financial Officer) | Sale | 2,257 | 90.74 | 204,809 |
| 2020-11-12 | Benevich Eric (Chief Commercial Officer) | Sale | 2,257 | 90.71 | 204,723 |
| 2020-11-12 | Gano Kyle (Chief Business Development Officer) | Sale | 2,257 | 90.73 | 204,770 |
| 2020-11-12 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 2,257 | 90.73 | 204,775 |
| 2020-11-12 | Lippoldt Darin (Chief Legal Officer) | Sale | 2,257 | 90.72 | 204,755 |
| 2020-11-12 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 2,257 | 90.73 | 204,784 |
| 2020-11-12 | Bozigian Haig P. (Chief Development Officer) | Sale | 2,257 | 90.74 | 204,806 |
| 2020-11-12 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 3,390 | 90.78 | 307,747 |
| 2020-11-02 | Benevich Eric (Chief Commercial Officer) | Sale | 20,595 | 96.53 | 1,987,973 |
| 2020-11-02 | Benevich Eric (Chief Commercial Officer) | Option Ex | 20,595 | 35.99 | 741,214 |
| 2020-10-02 | Cooke Julie (Chief Human Resources Officer) | Sale | 987 | 95.26 | 94,021 |
| 2020-08-05 | Cooke Julie (Chief Human Resources Officer) | Sale | 2,257 | 118.91 | 268,382 |
| 2020-08-05 | Roberts Eiry (Chief Medical Officer) | Sale | 2,257 | 118.84 | 268,226 |
| 2020-08-05 | Abernethy Matt (Chief Financial Officer) | Sale | 2,257 | 118.90 | 268,355 |
| 2020-08-05 | Benevich Eric (Chief Commercial Officer) | Sale | 2,257 | 118.85 | 268,253 |
| 2020-08-05 | Gano Kyle (Chief Business Development Officer) | Sale | 2,257 | 118.87 | 268,285 |
| 2020-08-05 | Lloyd-smith Malcolm (Chief Regulatory Officer) | Sale | 2,257 | 118.86 | 268,278 |
| 2020-08-05 | Lippoldt Darin (Chief Legal Officer) | Sale | 2,257 | 118.87 | 268,296 |
| 2020-08-05 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 2,257 | 118.83 | 268,199 |
| 2020-08-05 | Bozigian Haig P. (Chief Development Officer) | Sale | 2,257 | 118.89 | 268,323 |
| 2020-08-05 | Gorman Kevin Charles (Chief Executive Officer) | Sale | 3,390 | 118.91 | 403,101 |
| 2020-07-09 | Lippoldt Darin (Chief Legal Officer) | Sale | 1,657 | 136.02 | 225,385 |
| 2020-07-09 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 1,657 | 35.99 | 59,635 |
| 2020-06-23 | Roberts Eiry (Chief Medical Officer) | Sale | 5,000 | 130.00 | 650,000 |
| 2020-06-23 | Roberts Eiry (Chief Medical Officer) | Option Ex | 5,000 | 77.81 | 389,050 |
| 2020-06-23 | Lippoldt Darin (Chief Legal Officer) | Sale | 5,000 | 130.00 | 650,000 |
| 2020-06-23 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 5,000 | 32.99 | 164,950 |
| 2020-06-11 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 5,571 | 37.41 | 208,394 |
| 2020-05-19 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 42,749 | 126.35 | 5,401,464 |
| 2020-05-19 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 10,000 | 35.99 | 359,900 |
| 2020-05-18 | Lippoldt Darin (Chief Legal Officer) | Sale | 5,000 | 120.00 | 600,000 |
| 2020-05-18 | Lippoldt Darin (Chief Legal Officer) | Option Ex | 5,000 | 32.99 | 164,950 |
| 2020-05-18 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 10,000 | 119.98 | 1,199,800 |
| 2020-05-18 | Grigoriadis Dimitri E. (Chief Research Officer) | Option Ex | 10,000 | 35.99 | 359,900 |
| 2020-05-12 | Bozigian Haig P. (Chief Development Officer) | Sale | 61,555 | 114.94 | 7,075,377 |
| 2020-05-12 | Bozigian Haig P. (Chief Development Officer) | Option Ex | 61,555 | 60.44 | 3,720,507 |
| 2020-05-07 | Abernethy Matt (Chief Financial Officer) | Sale | 15,000 | 110.21 | 1,653,135 |
| 2020-05-07 | Abernethy Matt (Chief Financial Officer) | Option Ex | 15,000 | 73.60 | 1,104,000 |
| 2020-05-07 | Grigoriadis Dimitri E. (Chief Research Officer) | Sale | 8,682 | 105.44 | 915,456 |
| 2020-04-28 | Abernethy Matt (Chief Financial Officer) | Sale | 1,741 | 102.49 | 178,435 |
Insider trading activities including stock purchases, stock sales, and option exercises
of NBIX listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Neurocrine Biosciences Inc (symbol NBIX,
CIK number 914475) see
the Securities and Exchange Commission (SEC) website.